Lifeboat Foundation

GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK). The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.

Used as a first-line treatment and an alternative to chemotherapy and surgery, Jemperli cured cancer in all patients, showing “an unprecedented 100% clinical complete response rate.” Tests that followed showed no evidence of remaining tumors. Moreover, the first 24 of the 42 patients were observed after an average time of 26.3 months, and they showed no signs of cancer resurfacing.

GSK will test the drug in additional studies involving certain types of colorectal cancers.

GCC19CART has previously been evaluated in an investigator-initiated clinical trial (ChiCTR2000040645) in China for the treatment of relapsed/refractory metastatic colorectal cancer (r/r mCRC).² Data from that trial showing improvements over standard of care (SOC) third-line therapies were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14–19, 2023, in Orlando, Florida. Among the 21 patients included in the efficacy analysis, superior results were observed in patients (n=8) who received the higher dose level (2×10⁶ CAR-T cells/kg; DL2) than in patients (n=13) who received the lower dose level (1×10⁶ CAR-T cells/kg; DL1). The objective response rate was 50% (n=4) for DL2, 15% (n=2) for DL1, and 29% (n=6) for all patients.

“The new AE specific to this product is diarrhea because the target is guanylate cyclase 2C (GCC), which plays a role in intestinal homeostasis… So, that’s expected, theoretically,” Victor Lu, PhD, the chief technology officer of Innovative Cellular Therapeutics, who presented the data, said during his presentation.2 “Most patients treated with this product experienced diarrhea, but it can be controlled and because of the diarrhea management most of the patients actually recovered very quickly.”

GCC19CART targets both GCC and CD19.¹ It was designed using ICT’s CoupledCAR platform, which combines 2 CAR T cells engineered to release cytokines that are thought to promote proliferation and infiltration.³ The platform was designed following observations that CD19-directed CAR T cells also stimulated the immune system, which could lead to increase proliferation for other CAR T cells, specifically those directed toward solid tumor antigens, like GCC.

In the brain, timekeeping is done with neurons that relax at different rates after receiving a signal; now memristors—hardware analogs of neurons—can do that too.

Artificial neural networks may soon be able to process time-dependent information, such as audio and video data, more efficiently. The first memristor with a ‘relaxation time’ that can be tuned is reported today in Nature Electronics, in a study led by the University of Michigan.

Energy Efficiency and AI.

NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans, as well as new generative AI breakthroughs coming soon to the platform.

The father and son exploring global longevity, inspiring healthier lives and investigating scientific breakthroughs on the horizon.

Transistors are the basis for microchips and the whole electronic industry. The invention of transistors, by Bardeen and Brattain in 1947, awarded with a Nobel prize, is regarded as one of the most important discoveries of the 20th century.

Innovative infrared sensors developed by NASA increase resolution for Earth and space imaging, promising advancements in environmental monitoring and planetary science.

A newly developed infrared camera featuring high resolution and equipped with a range of lightweight filters has the potential to analyze sunlight reflected from Earth’s upper atmosphere and surface, enhance forest fire alerts, and uncover the molecular composition of other planets.

These cameras are equipped with sensitive, high-resolution strained-layer superlattice sensors, originally developed at NASA’s Goddard Space Flight Center in Greenbelt, Maryland, funded through the Internal Research and Development (IRAD) program.

Gas bubbling up from a lava-covered surface on the exoplanet 55 Cancri e may feed an atmosphere rich in carbon dioxide or carbon monoxide.

Located a mere 41 light years from Earth, the exoplanet 55 Cancri e is so intensely hot that scientists once doubted its ability to sustain an atmosphere. However, a recent study conducted by a national team of scientists suggests 55 Cancri e may be the first rocky exoplanet confirmed to have an atmosphere.

Published in Nature, the paper titled “A Secondary Atmosphere on the Rocky Exoplanet 55 Cnc e” was authored by researchers from NASA’s Jet Propulsion Laboratory, the California Institute of Technology, the University of Chicago, the University of New Mexico (UNM).

The research explores the potential of supercapacitors as a faster-charging and longer-lasting alternative to traditional batteries.